A pragmatic approach to enterprise AI

A Pragmatic Approach to Trial Design - ILCN.org (ILCN/WCLC)

With multiple negative phase III studies and limited FDA-approved options after progression on immunotherapy and chemotherapy, there is a pressing need for effective therapies for advanced non-small cell lung cancer (NSCLC). Karen L. Reckamp, MD, MS In the randomized phase II Lung-MAP (S1800A) study, the combination of ramucirumab with pembrolizumab demonstrated an improvement in overall survival (OS), with a median OS of 14.5 months compared t…

Why Most AI Pilots Never Reach Production

With only 13% of companies ready to scale AI, here’s what enterprise leaders need to know to turn pilots into production and hype into real ROI.

A pragmatic approach to enterprise AI

2024 is over. So, too, should be the approach to AI of throwing everything at the wall to see what sticks. It's 2025, and to get the most out of AI, businesses must be more pragmatic.Early investments yielded small successes in the market. But the juice hasn't always been worth the squeeze. Eight in 10 AI projects fail or encounter significant setbacks or cost overruns. There is no doubt that companies will continue to invest in AI. But in 2025,…

AI adoption surges across APAC even as enterprise spending and strategy fall short

A new study by ServiceNow has revealed a growing disconnect between enterprise ambition and execution when it comes to artificial intelligence (AI) in Asia Pacific (APAC). The study showed Tuesday that while business leaders are optimistic about AI’s potential, most organizations are reducing their AI budgets. This is a sign that strategic misalignment, governance gaps, and fragmented deployment are stalling returns and undermining confidence. A…